Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation

Blood

Volumn 123, Issue 10, 2014, Pages 1483-1486

  Boulad, Farid ^a   Wang, Xiuyan ^a   Qu, Jinrong ^a   Taylor, Clare ^a   Ferro, Leda ^a   Karponi, Garyfalia ^a   Bartido, Shirley ^a   Giardina, Patricia ^b   Heller, Glenn ^a   Prockop, Susan E ^a   Maggio, Aurelio ^c   Sadelain, Michel ^a   Rivier̀e, Isabelle ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; HYDROXYUREA; LENTIVIRUS VECTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CLINICAL ARTICLE; EXPRESSION VECTOR; GENE TRANSFER; GLOBIN GENE; GOOD MANUFACTURING PRACTICE; HEMATOPOIETIC STEM CELL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; LEUKAPHERESIS; LEUKOCYTE COUNT; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL MOBILIZATION; THALASSEMIA MAJOR;

ANIMALS; ANTIGENS, CD34; BETA-GLOBINS; BETA-THALASSEMIA; COLONY-FORMING UNITS ASSAY; DISEASE MODELS, ANIMAL; ERYTHROID PRECURSOR CELLS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROGRAFTS; HUMANS; MICE; TRANSDUCTION, GENETIC;

EID: 84897540191     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-507178     Document Type: Article

References (25)

1. Weatherall DJ, Clegg JB. The Thalassemia Syndrome. Oxford, United Kingdom: Blackwell Scientific; 1981
2. Orkin S, Nathan DG. Hematology of Infancy and Childhood. Philadelphia, PA: W.B. Saunders; 1998.
3. Stamatoyannopoulos G, Nienhuis AW, Majerus P, Varmus H. The Molecular Basis of Blood Diseases. Philadelphia, PA: W. B. Saunders; 2001.
4. Lucarelli G, Isgrò A, Sodani P, Gaziev J. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med. 2012;2(5):a011825.
5. Boulad F. Hematopoietic Stem Cell Transplantation for the Treatment of β-Thalassemia. New York, NY: Informa Healthcare; 2006.
6. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193. (Pubitemid 39390442)
7. Sadelain M. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr Opin Hematol. 2006;13(3):142-148.
8. May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L, Sadelain M. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature. 2000;406(6791):82-86. (Pubitemid 30460215)
9. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood. 2002;99(6):1902-1908. (Pubitemid 34525467)
10. Rivella S, May C, Chadburn A, Rivière I, Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood. 2003;101(8):2932-2939. (Pubitemid 36857977)
11. Lisowski L, Sadelain M. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice. Blood. 2007;110(13):4175-4178. (Pubitemid 351377780)
12. Perumbeti A, Malik P. Therapy for beta-globinopathies: a brief review and determinants for successful and safe correction. Ann N Y Acad Sci. 2010;1202:36-44.
13. Persons DA. The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in beta-thalassemia patients. Ann N Y Acad Sci. 2010;1202:69-74.
14. Sadelain M, Rivière I, Wang X, et al. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. Ann N Y Acad Sci. 2010;1202:52-58.
15. Yannaki E, Emery DW, Stamatoyannopoulos G. Gene therapy for β-thalassaemia: the continuing challenge. Expert Rev Mol Med. 2010;12:e31.
16. Sadelain M, Boulad F, Lisowki L, Moi P, Riviere I. Stem cell engineering for the treatment of severe hemoglobinopathies. Curr Mol Med. 2008;8(7):690-697.
17. Urbinati F, Arumugam P, Higashimoto T, Perumbeti A, Mitts K, Xia P, Malik P. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3′LTR. Mol Ther. 2009;17(9):1527-1536.
18. Rivière I, Dunbar CE, Sadelain M. Hematopoietic stem cell engineering at a crossroads. Blood. 2012;119(5):1107-1116.
19. Li K, Wong A, Li CK, et al. Granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in beta-thalassemia patients: kinetics of mobilization and composition of apheresis product. Exp Hematol. 1999;27(3):526-532. (Pubitemid 29125062)
20. Yannaki E, Papayannopoulou T, Jonlin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 2012;20(1):230-238.
21. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy. 2009;11(4):464-471.
22. Frittoli MC, Biral E, Cappelli B, et al. Bone marrow as a source of hematopoietic stem cells for human gene therapy of β-thalassemia. Hum Gene Ther. 2011;22(4):507-513.
23. Breda L, Casu C, Gardenghi S, et al. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients. PLoS ONE. 2012;7(3):e32345.
24. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672. (Pubitemid 30241569)
25. Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 2000;25(4):401-404. (Pubitemid 30114034)